Arcturus Therapeutics Holdings Inc. (ARCT): Price and Financial Metrics
GET POWR RATINGS... FREE!
ARCT POWR Grades
- ARCT scores best on the Growth dimension, with a Growth rank ahead of 86.03% of US stocks.
- ARCT's strongest trending metric is Growth; it's been moving up over the last 179 days.
- ARCT's current lowest rank is in the Stability metric (where it is better than 3.08% of US stocks).
ARCT Stock Summary
- Of note is the ratio of ARCTURUS THERAPEUTICS HOLDINGS INC's sales and general administrative expense to its total operating expenses; only 8.47% of US stocks have a lower such ratio.
- ARCT's price/sales ratio is 9.01; that's higher than the P/S ratio of 86.91% of US stocks.
- Revenue growth over the past 12 months for ARCTURUS THERAPEUTICS HOLDINGS INC comes in at 366.35%, a number that bests 97.29% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to ARCTURUS THERAPEUTICS HOLDINGS INC are XBIT, CMRX, QURE, CRNX, and RAPT.
- Visit ARCT's SEC page to see the company's official filings. To visit the company's web site, go to www.arcturusrx.com.
ARCT Valuation Summary
- In comparison to the median Healthcare stock, ARCT's price/sales ratio is 359.09% higher, now standing at 10.1.
- Over the past 108 months, ARCT's price/earnings ratio has gone up 138.2.
Below are key valuation metrics over time for ARCT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ARCT | 2022-09-01 | 10.1 | 2.4 | -2.5 | -1.4 |
| ARCT | 2022-08-31 | 9.2 | 2.2 | -2.3 | -1.1 |
| ARCT | 2022-08-30 | 9.2 | 2.2 | -2.3 | -1.1 |
| ARCT | 2022-08-29 | 9.6 | 2.3 | -2.4 | -1.2 |
| ARCT | 2022-08-26 | 9.8 | 2.3 | -2.4 | -1.3 |
| ARCT | 2022-08-25 | 10.9 | 2.6 | -2.7 | -1.5 |
ARCT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ARCT has a Quality Grade of D, ranking ahead of 24% of graded US stocks.
- ARCT's asset turnover comes in at 0.02 -- ranking 368th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ARCT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.020 | 1 | -32.552 |
| 2021-03-31 | 0.025 | 1 | -19.685 |
| 2020-12-31 | 0.037 | 1 | -30.242 |
| 2020-09-30 | 0.066 | 1 | -5.591 |
| 2020-06-30 | 0.115 | 1 | -4.145 |
| 2020-03-31 | 0.244 | 1 | -2.814 |
ARCT Price Target
For more insight on analysts targets of ARCT, see our ARCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $78.46 | Average Broker Recommendation | 1.88 (Hold) |
ARCT Stock Price Chart Interactive Chart >
ARCT Price/Volume Stats
| Current price | $14.42 | 52-week high | $58.09 |
| Prev. close | $14.75 | 52-week low | $11.70 |
| Day low | $14.32 | Volume | 42,909 |
| Day high | $14.99 | Avg. volume | 581,938 |
| 50-day MA | $17.32 | Dividend yield | N/A |
| 200-day MA | $23.60 | Market Cap | 383.23M |
Arcturus Therapeutics Holdings Inc. (ARCT) Company Bio
Arcturus Therapeutics Ltd a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company was founded in 2008 and is based in Tel Aviv, Israel.
Latest ARCT News From Around the Web
Below are the latest news stories about ARCTURUS THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate ARCT as an investment opportunity.
Arcturus Therapeutics to Attend the Following Investor ConferencesSAN DIEGO, September 01, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences. |
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza ResponseSAN DIEGO, August 31, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has obtained an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority (BARDA). The award provides $63.2 million over three years to sup |
Arcturus' COVID-19 Booster Shows Durability Against Omicron VariantsArcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced updated data from its ongoing ARCT-154 booster clinical trial. The new results demonstrate a broad neutralizing antibody response against omicron variants of concern, including BA.5, lasting up to at least six months after administering a low-dose (5 mcg) ARCT-154 booster. “Our next generation low-dose self-amplifying (STARR™) mRNA technology continues to differentiate itself from conventional mRNA vaccine technology,” said Joseph Payne |
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 VaccineSAN DIEGO, August 18, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", "Arcturus Therapeutics", Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced updated data from its ongoing ARCT-154 booster clinical trial. The new results demonstrate broad neutralizing antibody response against Omicron variants of co |
New Forecasts: Here's What Analysts Think The Future Holds For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Shareholders in Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) may be thrilled to learn that the analysts have... |
ARCT Price Returns
| 1-mo | -20.90% |
| 3-mo | -4.31% |
| 6-mo | -21.63% |
| 1-year | -74.07% |
| 3-year | 40.00% |
| 5-year | 93.43% |
| YTD | -61.04% |
| 2021 | -14.68% |
| 2020 | 299.08% |
| 2019 | 139.96% |
| 2018 | -43.02% |
| 2017 | -45.92% |
Loading social stream, please wait...